| 0.174 -0.04 (-18.69%) | 02-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.27 | 1-year : | 0.4 |
| Resists | First : | 0.23 | Second : | 0.34 |
| Pivot price | 0.14 |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.12 |
| MA(100) : | 0.43 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.9 |
D(3) : | 12 |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 4.93 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SIEN ] has closed above bottom band by 13.4%. Bollinger Bands are 16.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.06 - 0.06 | 0.06 - 0.06 |
| Close: | 0.06 - 0.06 | 0.06 - 0.06 |
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Thu, 11 Apr 2024
StockNews.com Initiates Coverage on Sientra (NASDAQ:SIEN) - Defense World
Wed, 03 Apr 2024
Sientra (NASDAQ:SIEN) Research Coverage Started at StockNews.com - Defense World
Fri, 16 Feb 2024
Sientra's Nasdaq Delisting and Chapter 11 Bankruptcy Filing - TipRanks.com - TipRanks
Tue, 13 Feb 2024
Sientra seeks buyer during Chapter 11 proceedings By Investing.com - Investing.com UK
Tue, 13 Feb 2024
Sientra drops on filing of voluntary Chapter 11 Bankruptcy (NASDAQ:SIEN) - Seeking Alpha
Tue, 13 Feb 2024
Breast-Implant Maker Sientra Files for Bankruptcy - The Wall Street Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 12 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.6 (%) |
| Held by Institutions | 17 (%) |
| Shares Short | 1,310 (K) |
| Shares Short P.Month | 1,360 (K) |
| EPS | -5.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.82 |
| Profit Margin | -65.5 % |
| Operating Margin | -48.1 % |
| Return on Assets (ttm) | -20.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -13.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.55 |
| EBITDA (p.s.) | -3.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | 8 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | -0.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|